Medication use patterns and two-year outcome in first-admission patients with major depressive disorder with psychotic features

Comprehensive Psychiatry

Volumn 48, Issue 6, 2007, Pages 497-503

  Craig, Thomas J ^a   Grossman, Steven ^b   Bromet, Evelyn J ^b   Fochtmann, Laura J ^b   Carlson, Gabrielle A ^b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONVALESCENCE; DEPRESSIVE PSYCHOSIS; DISEASE COURSE; DRUG USE; ELECTROCONVULSIVE THERAPY; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MONOTHERAPY; PSYCHIATRIC DIAGNOSIS; REMISSION; SCORING SYSTEM; SELF REPORT; TELEMEDICINE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; PSYCHOTIC DISORDERS; RECOVERY OF FUNCTION; REMISSION INDUCTION;

EID: 35348859576     PISSN: 0010440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.comppsych.2007.06.005     Document Type: Article

References (32)

1. Rothschild A.J., Bates K.S., Boehringer K.L., and Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry 60 (1999) 116-118
2. Dannon P.N., Lowengrub K., Gonopolski Y., and Kotler M. Current and emerging somatic treatment strategies in psychotic major depression. Expert Rev Neurotherapeutics 6 (2006) 73-80
3. Schatzberg A.F., and Rothschild A.J. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?. Am J Psychiatry 150 (1992) 733-745
4. Coryell W., Lavori P., Endicott J., Keller M., and VanEerdewegh M. Outcome in schizoaffective, psychotic and nonpsychotic depression: course during a six-to 24-month follow-up. Arch Gen Psychiatry 41 (1984) 787-791
5. Kendler K.S. Mood-incongruent psychotic affective illness. a historical and empirical review. Arch Gen Psychiatry 48 (1991) 362-369
6. Maj M., Pirozzi R., and Caprio E.L. Major depression with mood incongruent psychotic features: a distinct entity or a more severe subtype of depression?. Acta Psychiatr Scand 82 (1990) 439-444
7. Charney D.S., and Nelson J.C. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry 138 (1981) 328-333
8. Lykouras E., Malliaras D., Christodoulou G.N., Papakostas Y., Voulgari A., Tzonou A., et al. Delusional depression: phenomenology and response to treatment. A prospective study. Acta Psychiatr Scand 73 (1986) 324-329
9. Tohen M., Hennen J., Zarate Jr. C.M., Baldessarini R.J., Strakowski S.M., Stoll A.L., et al. Two-year syndromal and functional recovery in 219 cases of first episode major affective disorder with psychotic features. Am J Psychiatry 157 (2000) 220-228
10. Wykstra J., Lijmer J., Balk F., Geddes J., and Nolen W.A. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 4 (2005) CD004044
11. Bromet E., Schwartz J., Fennig S., Geller L., Jandorf L., Kovasznay B., et al. The epidemiology of psychosis: the Suffolk County mental health project. Schizophr Bull 18 (1992) 243-255
12. Spitzer R.L., Williams J., Gibbon M., and First M.B. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 49 (1992) 624-629
13. Fennig S., Kovasznay B., Rich C., Ram R., Pato C., Miller A., et al. Six-month stability of psychiatric diagnoses in first admission patients with psychosis. Am J Psychiatry 151 (1994) 1200-1208
14. Gibson P.J., Lavelle J., and Bromet E. Building a useful pharmacotherapy data set from multiple sources. Poster presented at the Annual Conference of the Association of Health Services Researchers, Chicago, Ill (1999)
15. Patterson D.A., and Lee M.S. Field trial of the Global Assessment of Functioning Scale-Modified. Am J Psychiatry 152 (1995) 1386-1388
16. Jablensky A., Sartorius N., Ernberg G., Anker M., Korten A., Cooper J.E., et al. Schizophrenia: manifestations, incidence and course in different cultures: a World Health Organization ten-country study. Psychol Med Monogr Suppl 20 (1992) 1-97
17. Mueller T.I., Leon A.C., Keller M.B., Solomon D.A., Endicott J., Coryell W., et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 156 (1999) 1000-1006
18. Keller M.B., Lavori P.W., Rice J., Coryell W., and Hirschfeld R.M.A. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. Am J Psychiatry 143 (1986) 24-28
19. Keller M.B., Harrison W., Fawcett J.A., Gelenberg A., Hirschfeld R.M., Klein D., et al. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacol Bull 31 (1995) 205-212
20. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. STAR*D study team: evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163 (2006) 28-40
21. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., et al. STAR*D study team: bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354 (2006) 1231-1242
22. Fava M., Rush A.J., Wisniewski S.R., Alpert J.E., McGrath P.J., Thase M.E., et al. A comparison of mirtazapine and nortriptyline following two consecutive failed treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163 (2006) 1161-1172
23. McGrath P.J., Stewart J.W., Fava M., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry (2006) 1531-1541
24. Trivedi M.H., Fava M., Wisniewski S.R., Thase M.E., Quitkin F., Warden D., et al. STAR*D team: medication augmentation after the failure of SSRIs for depression. N Engl J Med 354 (2006) 1243-1252
25. Nierenberg A.A., Fava M., Trivedi M.H., Wisniewski S.R., Thase M.E., McGrath P.J., et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163 (2006) 1519-1530
26. Maj M., Arena F., Lovero N., Pirozzi R., and Kemali D. Factors associated with response to lithium prophylaxis in DSMIII major depression and bipolar disorder. Pharmacopsychiatry 18 (1985) 309-313
27. Valenstein M., McCarthy J.F., Austin K.L., Greden J.F., Young E.A., and Blow F.C. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 163 (2006) 1219-1225
28. Flint A.J., and Rifat S.L. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry 13 (1998) 23-28
29. Petrides G., Fink M., Husain M.M., Knapp R.G., Rush A.J., Mueller M., et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. JECT 17 (2001) 244-253
30. Cochran S.D. Compliance with lithium regimens in the outpatient treatment of bipolar affective disorders. J Compliance Health Care 1 (1986) 153-170
31. Rothschild A.J., Williamson D.J., Tohen M.F., Schatzberg A., Andersen S.W., Van Campen L.E., et al. Olanzapine-fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 24 (2004) 365-373
32. Spiker D.G., Weiss J.C., Dealy R.S., Griffin S.J., Hanin I., Neil J.F., et al. The pharmacological treatment of delusional depression. Am J Psychiatry 142 (1985) 430-436